Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jan 2017

Suda Kenichi, Bunn Paul A, Rivard Christopher J, Mitsudomi Tetsuya, Hirsch Fred R

Abstract excerpt

Diverse molecular mechanisms that confer acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in lung cancers with sensitive EGFR mutations have been reported. However, it is not realistic to analyze for all these mechanisms at the time of resistance in clinical practice and establish adequate treatment targeting these numerous resistance mechanisms. Therefore, we believe that we should move our research...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 27642065
DOI: 10.1016/j.jtho.2016.09.003
PMCID: PMC5327855

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.PMID 27642065Read ↗

[Advances in research on primary resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients].Semantic proximity Read ↗

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.Semantic proximity Read ↗

Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical TreatmentSemantic proximity Read ↗

Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer.Semantic proximity Read ↗

EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.Semantic proximity Read ↗

The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC.Semantic proximity Read ↗

The resistance mechanisms and treatment strategies for <i>EGFR</i>-mutant advanced non-small-cell lung cancerSemantic proximity Read ↗

Emerging treatment for advanced lung cancer with EGFR mutation.Semantic proximity Read ↗

[The mechanisms of resistance to EGFR-TKIs and challenges to overcome resistance in EGFR mutant non-small cell lung cancer].Semantic proximity Read ↗

Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung CancerSemantic proximity Read ↗

[Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].Semantic proximity Read ↗

[Molecular mechanisms of targeted drug resistance in lung cancer and its therapeutic strategy].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.